Intellia Therapeutics reported a quarterly loss of $0.81 per share, beating the Zacks Consensus Estimate for a loss of $0.92. The loss also improved from $1.10 per share a year ago, indicating year-over-year bottom-line progress. The update is modestly positive, but the article provides no revenue, guidance, or other catalysts.
Intellia Therapeutics reported a quarterly loss of $0.81 per share, beating the Zacks Consensus Estimate for a loss of $0.92. The loss also improved from $1.10 per share a year ago, indicating year-over-year bottom-line progress. The update is modestly positive, but the article provides no revenue, guidance, or other catalysts.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
